Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 2, 2011, Pages 419-432

  Boldo, Angela ^a   White, William B ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure monitoring; Hormone therapy; Menopause; Oral contraceptives; Postmenopausal

Indexed keywords

BALZIVA; BREVICOM; CAMILLA; CAPTOPRIL; CHLORMADINONE ACETATE; DEPO SUBQ PROVERA; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DEXTROMETHORPHAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; ETYNODIOL DIACETATE; FEMCOM FE; GESTAGEN; GESTODENE; HYDROCHLOROTHIAZIDE; JOLESSA; JUNEL 21 1 20; JUNEL 21 1 5 30; LEVONORGESTREL; LOESTRIN 21 1 20; LOESTRIN 21 1 5 30; LOESTRIN 24 FE 1 20; LOESTRIN FE 1 5 30; LOSARTAN; LOW OGESTREL; LUTERA; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MESTRANOL PLUS NORETHISTERONE; MICROGESTIN 1 20; MICROGESTIN 1 5 30; MICROGESTIN FE 1 20; MICROGESTIN FE 1 5 30; NECON 0 5 35; NECON 1 35; NECON 1 50; NECON 7 7 7 7; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; NORGESTREL; NORINYL 1 35; OCELLA; ORAL CONTRACEPTIVE AGENT; ORTHO NOVUM 1 35; ORTHO NOVUM 7 7 7; ORTHO VERA; OTHROMICRONOR; PLACEBO; PROTIA; TRI PREVIFEM; TRI SPRINTEC; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOVIA 1 35;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ACTIVATION; FEMALE; HEART HYPERTROPHY; HEART PROTECTION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION;

AGED; ANIMALS; BLOOD PRESSURE; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE; RENIN-ANGIOTENSIN SYSTEM; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 79955729850     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.01.008     Document Type: Review

References (62)

1. Chandra A., Martinez G.M., Mosher W.D., et al. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat 23 2005, (25):1-160.
2. Shufelt C.L., Bairey Merz C.N. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009, 53:221-231.
3. Wilson E.S., Cruickshank J., McMaster M., et al. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen. Br J Obstet Gynaecol 1984, 91:1254-1260.
4. Dong W., Colhoun H.M., Poulter N.R. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J Hypertens 1997, 15:1063-1068.
5. Meade T.W., Haines A.P., North W.R., et al. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. Lancet 1977, 2:948-951.
6. Nichols M., Robinson G., Bounds W., et al. Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception 1993, 47:367-376.
7. Chasan-Taber L., Willett W.C., Manson J.E., et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996, 94:483-489.
8. Narkiewicz K., Graniero G.R., D'Este D., et al. Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. A case-control study. Am J Hypertens 1995, 8:249-253.
9. Lubianca J.N., Faccin C.S., Fuchs F.D. Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception 2003, 67:19-24.
10. Lubianca J.N., Moreira L.B., Gus M., et al. Stopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension. J Hum Hypertens 2005, 19:451-455.
11. Cardoso F., Polonia J., Santos A., et al. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet 1997, 59:237-243.
12. Oelkers W., Foidart J.M., Dombrovicz N., et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995, 80:1816-1821.
13. Gordon M.S., Chin W.W., Shupnik M.A. Regulation of angiotensinogen gene expression by estrogen. J Hypertens 1992, 10:361-366.
14. Kang A.K., Duncan J.A., Cattran D.C., et al. Effect of oral contraceptives on the renin angiotensin system and renal function. Am J Physiol Regul Integr Comp Physiol 2001, 280:R807-R813.
15. Cherney D.Z., Scholey J.W., Cattran D.C., et al. The effect of oral contraceptives on the nitric oxide system and renal function. Am J Physiol Renal Physiol 2007, 293:F1539-F1544.
16. Saruta T., Nakamura R., Nagahama S., et al. Effects of angiotensin II analog on blood pressure, renin and aldosterone in women on oral contraceptives and toxemia. Gynecol Obstet Invest 1981, 12:11-20.
17. Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 2004, 217:255-261.
18. Arias-Loza P.A., Hu K., Schafer A., et al. Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. Hypertension 2006, 48:994-1001.
19. Khaw K.T., Peart W.S. Blood pressure and contraceptive use. Br Med J (Clin Res Ed) 1982, 285:403-407.
20. Ribstein J., Halimi J.M., du Cailar G., et al. Renal characteristics and effect of angiotensin suppression in oral contraceptive users. Hypertension 1999, 33:90-95.
21. Preston R.A., Alonso A., Panzitta D., et al. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002, 15:816-822.
22. Preston R.A., Norris P.M., Alonso A.B., et al. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007, 14:408-414.
23. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801-1811.
24. Kaplan J.R., Manuck S.B., Anthony M.S., et al. Premenopausal social status and hormone exposure predict postmenopausal atherosclerosis in female monkeys. Obstet Gynecol 2002, 99:381-388.
25. Adams M.R., Anthony M.S., Manning J.M., et al. Low-dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys. Obstet Gynecol 2000, 96:250-255.
26. Stampfer M.J., Willett W.C., Colditz G.A., et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988, 319:1313-1317.
27. Dunn N., Thorogood M., Faragher B., et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999, 318:1579-1583.
28. Sidney S., Siscovick D.S., Petitti D.B., et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 1998, 98:1058-1063.
29. Tanis B.C., van den Bosch M.A., Kemmeren J.M., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001, 345:1787-1793.
30. Sidney S., Petitti D.B., Soff G.A., et al. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004, 70:3-10.
31. Gerstman B.B., Piper J.M., Tomita D.K., et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991, 133:32-37.
32. Jick H., Jick S.S., Gurewich V., et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995, 346:1589-1593.
33. Winkler U.H., Schindler A.E., Endrikat J., et al. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol. Contraception 1996, 53:75-84.
34. Endrikat J., Klipping C., Cronin M., et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 2002, 65:215-221.
35. Skouby S.O., Endrikat J., Dusterberg B., et al. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. Contraception 2005, 71:111-117.
36. Klipping C., Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005, 71:409-416.
37. Barkfeldt J., Virkkunen A., Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception 2001, 64:295-299.
38. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349:523-534.
39. Bar J., Lahav J., Hod M., et al. Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17beta-estradiol and medroxyprogesterone acetate in postmenopausal women. Thromb Haemost 2000, 84:695-700.
40. Nakano Y., Oshima T., Matsuura H., et al. Effect of 17beta-estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis. Arterioscler Thromb Vasc Biol 1998, 18:961-967.
41. Zerr-Fouineau M., Jourdain M., Boesch C., et al. Certain progestins prevent the enhancing effect of 17beta-estradiol on NO-mediated inhibition of platelet aggregation by endothelial cells. Arterioscler Thromb Vasc Biol 2009, 29:586-593.
42. Feuring M., Christ M., Roell A., et al. Alterations in platelet function during the ovarian cycle. Blood Coagul Fibrinolysis 2002, 13:443-447.
43. Rosin C., Brunner M., Lehr S., et al. The formation of platelet-leukocyte aggregates varies during the menstrual cycle. Platelets 2006, 17:61-66.
44. Roell A., Schueller P., Schultz A., et al. Effect of oral contraceptives and ovarian cycle on platelet function. Platelets 2007, 18:165-170.
45. Nakano Y., Oshima T., Ozono R., et al. Estrogen replacement suppresses function of thrombin stimulated platelets by inhibiting Ca(2+) influx and raising cyclic adenosine monophosphate. Cardiovasc Res 2002, 53:634-641.
46. Shifren J.L., Schiff I. Role of hormone therapy in the management of menopause. Obstet Gynecol 2010, 115:839-855.
47. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
48. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280:605-613.
49. Maclennan A.H., Broadbent J.L., Lester S., et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004, 4. CD002978.
50. Schiff I., Tulchinsky D., Cramer D., et al. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980, 244:1443-1445.
51. Burt V.L., Whelton P., Roccella E.J., et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25:305-313.
52. Staessen J.A., Ginocchio G., Thijs L., et al. Conventional and ambulatory blood pressure and menopause in a prospective population study. J Hum Hypertens 1997, 11:507-514.
53. Hernandez Schulman I., Raij L. Salt sensitivity and hypertension after menopause: role of nitric oxide and angiotensin II. Am J Nephrol 2006, 26:170-180.
54. Mallareddy M., Hanes V., White W.B. Drospirenone, a new progestogen, for postmenopausal women with hypertension. Drugs Aging 2007, 24:453-466.
55. Reckelhoff J.F., Fortepiani L.A. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004, 43:918-923.
56. Prelevic G.M., Kwong P., Byrne D.J., et al. A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002, 77:945-951.
57. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-1712.
58. White W.B., Pitt B., Preston R.A., et al. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005, 112:1979-1984.
59. White W.B., Hanes V., Chauhan V., et al. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006, 48:246-253.
60. Barrett-Connor E., Mosca L., Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006, 355:125-137.
61. Morgante G., Delia A., Musacchio M.C., et al. Effects of raloxifene therapy on plasma renin and aldosterone levels and blood pressure in postmenopausal women. Gynecol Endocrinol 2006, 22:376-380.
62. Sumino H., Ichikawa S., Kasama S., et al. Effects of raloxifene on brachial arterial endothelial function, carotid wall thickness, and arterial stiffness in osteoporotic postmenopausal women. Int Heart J 2010, 51:60-67.